Although further research is needed to substantiate the combined targeting of UBR5 and ICB therapy, the scattered success of ICB therapy, coupled with evidence of UBR5’s role in immune evasion, suggest that this combination could address the unmet therapeutic needs of MPNST patients with recurrent, unresectable, or metastatic disease. The gene discussed is UBR5; the disease is malignant peripheral nerve sheath tumor.